Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists

被引：13

作者：

Dzierba, CD ^{[1
]}

Takvorian, AG ^{[1
]}

Rafalski, M ^{[1
]}

Kasireddy-Polam, P ^{[1
]}

Wong, H ^{[1
]}

Molski, TF ^{[1
]}

Zhang, G ^{[1
]}

Li, YW ^{[1
]}

Lelas, S ^{[1
]}

Peng, Y ^{[1
]}

McElroy, JF ^{[1
]}

Zaczek, RC ^{[1
]}

Taub, RA ^{[1
]}

Combs, AP ^{[1
]}

Gilligan, PJ ^{[1
]}

Trainor, GL ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 23期

关键词：

D O I：

10.1021/jm049737f

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Corticotropin releasing factor (CRF) is the primary regulator of the hypothalamus-pituitary-adrenal (HPA) axis, coordinating the endocrine, behavioral, and autonomic responses to stress. It has been postulated that small molecules that can antagonize the binding of CRF, to its receptor may serve as a treatment for anxiety-related and/or affective disorders. Members within a series of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones, exemplified by compound 2 (IC50 = 0.70 nM), were found to be very potent antagonists of CRF1. Compound 8w showed high CRF1 receptor binding affinity and was examined further in vivo. The compound was efficacious in a defensive withdrawal model of anxiety in rats and had a long half-life and reasonable oral bioavailability in dog pharmacokinetic studies.

引用

页码：5783 / 5790

页数：8

共 34 条

[21]

McCarthy JR, 1999, CURR PHARM DESIGN, V5, P289

[22]

McCarthy JR, 1999, ANNU REP MED CHEM, V34, P11

[23] The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats [J].

McElroy, JF ;

Ward, KA ;

Zeller, KL ;

Jones, KW ;

Gilligan, PJ ;

He, LQ ;

Lelas, S .

PSYCHOPHARMACOLOGY, 2002, 165 (01) :86-92

[24] NEUROPEPTIDE CONCENTRATIONS IN THE CEREBROSPINAL-FLUID OF DEPRESSED-PATIENTS TREATED WITH ELECTROCONVULSIVE-THERAPY - CORTICOTROPIN-RELEASING FACTOR, BETA-ENDORPHIN AND SOMATOSTATIN [J].

NEMEROFF, CB ;

BISSETTE, G ;

AKIL, H ;

FINK, M .

BRITISH JOURNAL OF PSYCHIATRY, 1991, 158 :59-63

[25] ELEVATED CONCENTRATIONS OF CSF CORTICOTROPIN-RELEASING FACTOR-LIKE IMMUNOREACTIVITY IN DEPRESSED-PATIENTS [J].

NEMEROFF, CB ;

WIDERLOV, E ;

BISSETTE, G ;

WALLEUS, H ;

KARLSSON, I ;

EKLUND, K ;

KILTS, CD ;

LOOSEN, PT ;

VALE, W .

SCIENCE, 1984, 226 (4680) :1342-1344

[26]

OWENS MJ, 1993, CIBA F SYMP, V172, P296

[27]

OWENS MJ, 1991, PHARMACOL REV, V43, P425

[28] INCREASED NUMBERS OF CORTICOTROPIN-RELEASING HORMONE EXPRESSING NEURONS IN THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS OF DEPRESSED-PATIENTS [J].

RAADSHEER, FC ;

HOOGENDIJK, WJG ;

STAM, FC ;

TILDERS, FJH ;

SWAAB, DF .

NEUROENDOCRINOLOGY, 1994, 60 (04) :436-444

[29] POTENTIATION OF ACOUSTIC STARTLE BY CORTICOTROPIN-RELEASING FACTOR (CRF) AND BY FEAR ARE BOTH REVERSED BY ALPHA-HELICAL CRF (9-41) [J].

SWERDLOW, NR ;

BRITTON, KT ;

KOOB, GF .

NEUROPSYCHOPHARMACOLOGY, 1989, 2 (04) :285-292

[30] CORTICOTROPIN-RELEASING FACTOR MODULATES DEFENSIVE-WITHDRAWAL AND EXPLORATORY-BEHAVIOR IN RATS [J].

TAKAHASHI, LK ;

KALIN, NH ;

VANDENBURGT, JA ;

SHERMAN, JE .

BEHAVIORAL NEUROSCIENCE, 1989, 103 (03) :648-654

← 1 2 3 4 →